• Ascendis Pharma A/S published 2-year subgroup data from ApproaCH open-label extension through Week 104 in treatment-naïve children with achondroplasia aged 5 years or older.
• Week 52 primary endpoint showed higher annualized growth velocity with navepegritide versus placebo, with LS mean difference +1.78 cm/year (95% CI 1.22 to 2.33; p<0.0001) in children enrolled at age ≥5 years.
• Growth velocity gains were maintained through Week 104 in extension phase, alongside continued improvements in achondroplasia-specific height Z-scores.
• Safety profile through 104 weeks showed treatment-emergent adverse events in 88.7% of navepegritide-treated children enrolled at age ≥5 years, with injection-site reactions in 20.8%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.